123 related articles for article (PubMed ID: 2111246)
1. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.
Bialer M; Haj-Yehia A; Barzaghi N; Pisani F; Perucca E
Eur J Clin Pharmacol; 1990; 38(3):289-91. PubMed ID: 2111246
[TBL] [Abstract][Full Text] [Related]
2. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
Blotnik S; Bergman F; Bialer M
Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs.
Haj-Yehia A; Bialer M
J Pharm Sci; 1988 Oct; 77(10):831-4. PubMed ID: 3148708
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.
Winkler I; Blotnik S; Shimshoni J; Yagen B; Devor M; Bialer M
Br J Pharmacol; 2005 Sep; 146(2):198-208. PubMed ID: 15997234
[TBL] [Abstract][Full Text] [Related]
5. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid.
Radatz M; Ehlers K; Yagen B; Bialer M; Nau H
Epilepsy Res; 1998 Mar; 30(1):41-8. PubMed ID: 9551843
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.
Haj-Yehia A; Hadad S; Bialer M
Pharm Res; 1992 Aug; 9(8):1058-63. PubMed ID: 1409378
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
Bialer M; Hadad S; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Yagen B
Pharm Res; 1996 Feb; 13(2):284-9. PubMed ID: 8932450
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential.
Shekh-Ahmad T; Hen N; Yagen B; McDonough JH; Finnell RH; Wlodarczyk BJ; Bialer M
Epilepsia; 2014 Feb; 55(2):353-61. PubMed ID: 24313671
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.
Isoherranen N; White HS; Klein BD; Roeder M; Woodhead JH; Schurig V; Yagen B; Bialer M
Pharm Res; 2003 Aug; 20(8):1293-301. PubMed ID: 12948028
[TBL] [Abstract][Full Text] [Related]
10. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.
Haj-Yehia A; Bialer M
Pharm Res; 1989 Aug; 6(8):683-9. PubMed ID: 2510141
[TBL] [Abstract][Full Text] [Related]
11. Amidic derivatives of valproic acid, valpromide and valnoctamide, inhibit HSV-1 infection in oligodendrocytes.
Praena B; Bello-Morales R; de Castro F; López-Guerrero JA
Antiviral Res; 2019 Aug; 168():91-99. PubMed ID: 31132386
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid.
Mawasi H; Shekh-Ahmad T; Finnell RH; Wlodarczyk BJ; Bialer M
Epilepsy Behav; 2015 May; 46():72-8. PubMed ID: 25863940
[TBL] [Abstract][Full Text] [Related]
13. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.
Shekh-Ahmad T; Mawasi H; McDonough JH; Yagen B; Bialer M
Epilepsy Behav; 2015 Aug; 49():298-302. PubMed ID: 25979572
[TBL] [Abstract][Full Text] [Related]
14. [Valpromide, Valproic acid and removal of small intestine in the treatment of a chronic depression: a case report].
Benjelloun G; Blandin K; Fossati P
Encephale; 2004; 30(4):400-3. PubMed ID: 15538315
[TBL] [Abstract][Full Text] [Related]
15. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation.
Pisani F; Haj-Yehia A; Fazio A; Artesi C; Oteri G; Perucca E; Kroetz DL; Levy RH; Bialer M
Epilepsia; 1993; 34(5):954-9. PubMed ID: 8104783
[TBL] [Abstract][Full Text] [Related]
16. Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
Okada A; Kurihara H; Aoki Y; Bialer M; Fujiwara M
Birth Defects Res B Dev Reprod Toxicol; 2004 Feb; 71(1):47-53. PubMed ID: 14991910
[TBL] [Abstract][Full Text] [Related]
17. The disposition of valpromide in rats and the isolated perfused rat liver.
Billig H; Ziv E; Bar-On H; Bialer M
Drug Metab Dispos; 1990; 18(2):238-44. PubMed ID: 1971580
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase.
Kudin AP; Mawasi H; Eisenkraft A; Elger CE; Bialer M; Kunz WS
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28878165
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of valpromide.
Bialer M
Clin Pharmacokinet; 1991 Feb; 20(2):114-22. PubMed ID: 2029804
[TBL] [Abstract][Full Text] [Related]
20. Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.
Pisani F; Fazio A; Artesi C; Oteri G; Spina E; Tomson T; Perucca E
Br J Clin Pharmacol; 1992 Jul; 34(1):85-7. PubMed ID: 1352988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
